OneSkin Secures $20 Million Funding to Strengthen Its Role in Longevity Skincare

OneSkin, a biotech skincare brand, has raised $20 million in Series A funding from Prelude Growth Partners to boost its presence in the longevity beauty market. Founded in 2016 by four Brazilian scientists, OneSkin focuses on extending “skinspan” using a peptide called OS-01, which targets aging cells that contribute to inflammation and collagen breakdown. Though the brand wasn’t actively seeking new investment, Prelude Growth Partners’ enthusiasm and expertise made them ideal partners for this growth phase.

The funding marks a significant milestone, allowing OneSkin to replace an early investor with a partner better suited to support its expansion. The brand’s popular products include OS-01 Face, Body, Eye, Lip, and Hair, with celebrity fans such as Jennifer Aniston and Katy Perry. Previous investments were led by Selva Ventures and others, including investors like Camila Alves McConaughey.

In the broader industry, companies like L’Oréal and personalities like Martha Stewart are also exploring longevity skincare, with L’Oréal aiming to bring longevity beauty mainstream through brands like Lancôme, which offers products and devices focused on aging.